Parkinsonism & related disorders · 2026
Cortical myoclonus as a common and clinically actionable movement disorder phenotype of 22q11.2 deletion syndrome.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Reyes Nikolai Gil D, Grippe Talyta, Lira Victor S T, Angeloni Benedetta, Desai Naaz, Marras Connie, Boot Erik, Yuen Ryan K C, Lang Anthony E, Andrade Danielle M, Chen Robert, Bassett Anne S
Аннотация
BACKGROUND: Although myoclonus is known to be linked to genetic etiologies, its characterization in conditions associated with pathogenic copy number variation (CNV) remains limited.
OBJECTIVE: This study systematically characterized myoclonus in 22q11.2 microdeletion, the most common pathogenic CNV in humans.
METHODS: We identified individuals with neurophysiologically confirmed myoclonus from a large cohort of adults with 22q11.2 deletion syndrome (22q11.2DS) assessed between January 1996 and December 2025. We estimated prevalence, and analyzed clinical and neurophysiological features.
RESULTS: Among 295 neurologically assessed patients, 16 of the 42 unrelated individuals with clinically suspected myoclonus had neurophysiological data available for characterization. All 16 met predefined criteria for highly probable cortical myoclonus (minimum observed prevalence: 5.4%; 95% CI 3.4 - 8.6%), with eight meeting criteria for definite cortical myoclonus (minimum observed prevalence: 2.7%, 95% CI 1.4 - 5.3%). In 9 of the 12 patients with available follow-up clinical data, neurophysiological evaluation has led to changes in management.
CONCLUSIONS: The findings support cortical myoclonus as a relatively common and clinically actionable movement disorder in 22q11.2DS. As for Parkinson's disease, the results provide preliminary evidence supporting the chromosome 22q11.2 microdeletion as a potential risk-conferring CNV for cortical myoclonus, adding to the genetic heterogeneity associated with this movement disorder.
OBJECTIVE: This study systematically characterized myoclonus in 22q11.2 microdeletion, the most common pathogenic CNV in humans.
METHODS: We identified individuals with neurophysiologically confirmed myoclonus from a large cohort of adults with 22q11.2 deletion syndrome (22q11.2DS) assessed between January 1996 and December 2025. We estimated prevalence, and analyzed clinical and neurophysiological features.
RESULTS: Among 295 neurologically assessed patients, 16 of the 42 unrelated individuals with clinically suspected myoclonus had neurophysiological data available for characterization. All 16 met predefined criteria for highly probable cortical myoclonus (minimum observed prevalence: 5.4%; 95% CI 3.4 - 8.6%), with eight meeting criteria for definite cortical myoclonus (minimum observed prevalence: 2.7%, 95% CI 1.4 - 5.3%). In 9 of the 12 patients with available follow-up clinical data, neurophysiological evaluation has led to changes in management.
CONCLUSIONS: The findings support cortical myoclonus as a relatively common and clinically actionable movement disorder in 22q11.2DS. As for Parkinson's disease, the results provide preliminary evidence supporting the chromosome 22q11.2 microdeletion as a potential risk-conferring CNV for cortical myoclonus, adding to the genetic heterogeneity associated with this movement disorder.